Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
30574
Description
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00454532
Lien
https://clinicaltrials.gov/show/NCT00454532
Mots-clés
Versions (2)
- 16/06/2018 16/06/2018 -
- 16/06/2018 16/06/2018 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
16 juin 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Metastatic Breast Cancer NCT00454532
Eligibility Metastatic Breast Cancer NCT00454532
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Breast Cancer NCT00454532
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Gender | Age
Item
women 18 years or older
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Breast Carcinoma
Item
histologically confirmed breast cancer
boolean
C0678222 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Exception Secondary malignant neoplasm of bone
Item
clinical evidence of metastatic (stage iv) metastasis (other than bone metastasis)
boolean
C0346993 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0153690 (UMLS CUI [2,2])
C1705847 (UMLS CUI [2,1])
C0153690 (UMLS CUI [2,2])
Availability of Estrogen Receptor Status | Availability of Progesterone Receptor Status
Item
availability of estrogen and progesterone receptor status
boolean
C0470187 (UMLS CUI [1,1])
C1516974 (UMLS CUI [1,2])
C0470187 (UMLS CUI [2,1])
C1514471 (UMLS CUI [2,2])
C1516974 (UMLS CUI [1,2])
C0470187 (UMLS CUI [2,1])
C1514471 (UMLS CUI [2,2])
Measurable Disease Site Quantity
Item
at least one measurable disease site defined by recist criteria, 30 days prior to study therapy
boolean
C1513041 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1515974 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Phase Number | Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of female breast
Item
for the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. for the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer
boolean
C0205390 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C0677881 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0346993 (UMLS CUI [2,3])
C0237753 (UMLS CUI [1,2])
C0677881 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0346993 (UMLS CUI [2,3])
Life Expectancy
Item
life expectancy ≥ 12 weeks
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group performance status ≤2
boolean
C1520224 (UMLS CUI [1])
Childbearing Potential Contraceptive methods Quantity
Item
women of child bearing potential must agree to 2 forms of contraception during the course of the trial.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
C1542147 (UMLS CUI [1,2])
Informed Consent Unable | Informed Consent Unwilling
Item
inability to understand/unwillingness to sign a written informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
Adverse effects Chemotherapy Related | Adverse effects Therapeutic radiology procedure Related | Adverse effects Biological treatment Related | Adverse effects Hormone Therapy Related | Resolution failed
Item
any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator
boolean
C0879626 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C0879626 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0879626 (UMLS CUI [3,1])
C1531518 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
C0879626 (UMLS CUI [4,1])
C0279025 (UMLS CUI [4,2])
C0439849 (UMLS CUI [4,3])
C1514893 (UMLS CUI [5,1])
C0231175 (UMLS CUI [5,2])
C0392920 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C0879626 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0879626 (UMLS CUI [3,1])
C1531518 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
C0879626 (UMLS CUI [4,1])
C0279025 (UMLS CUI [4,2])
C0439849 (UMLS CUI [4,3])
C1514893 (UMLS CUI [5,1])
C0231175 (UMLS CUI [5,2])
Investigational New Drugs
Item
currently using an investigational agent
boolean
C0013230 (UMLS CUI [1])
Abnormality of the gastrointestinal tract
Item
clinically significant gastrointestinal abnormalities
boolean
C4023588 (UMLS CUI [1])
Coumadin Dose Therapeutic | Investigational New Drugs
Item
currently using coumadin at therapeutic doses or within 2 weeks of taking study medication
boolean
C0699129 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0302350 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2])
C0178602 (UMLS CUI [1,2])
C0302350 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2])
Palliative Radiation Therapy | Cancer treatment
Item
concurrent palliative radiation or anti-cancer treatment
boolean
C3898008 (UMLS CUI [1])
C0920425 (UMLS CUI [2])
C0920425 (UMLS CUI [2])
Pregnancy | Breast Feeding | Pregnancy test positive
Item
women who report pregnancy, are breast-feeding or have a positive pregnancy test
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0240802 (UMLS CUI [3])
C0006147 (UMLS CUI [2])
C0240802 (UMLS CUI [3])